Stage II Melanoma
Stage II melanoma is a localized but intermediate-to-high-risk form of skin cancer in which the tumor has grown deeper into the skin without spreading to nearby lymph nodes or distant organs. Early recognition and an individualized treatment plan are essential to improving outcomes.
Key Takeaways
- Stage II melanoma is confined to the primary tumor site but is thicker or ulcerated, placing it at elevated risk compared to earlier stages.
- Diagnosis relies on skin biopsy, tumor thickness measurement (Breslow depth), and sentinel lymph node evaluation.
- Wide local excision is the primary treatment, often supplemented by adjuvant immunotherapy or targeted therapy.
- Five-year survival rates for stage II melanoma range from approximately 65% to 90%, depending on substage.
- Regular follow-up and dermatologic surveillance remain critical after treatment.
Stage II Melanoma: Symptoms, Diagnosis, and Staging Criteria
Stage II melanoma symptoms often mirror those of earlier melanoma stages but involve lesions that have grown more deeply into the skin. Clinicians and patients alike use the ABCDE criteria—Asymmetry, Border irregularity, Color variation, Diameter greater than 6 mm, and Evolution—to identify suspicious moles or pigmented lesions. Lesions may appear as dark brown or black patches, sometimes with areas of red, white, or blue discoloration, and may bleed, itch, or develop surface changes over time.
The stage II melanoma symptoms and diagnosis process begins with a full-thickness excisional biopsy of the suspicious lesion. A pathologist then measures Breslow depth (tumor thickness in millimeters) and evaluates for ulceration, both of which determine the specific substage. Stage II is divided into substages IIA, IIB, and IIC based on increasing tumor thickness and the presence of ulceration, as outlined by the American Joint Committee on Cancer (AJCC) staging system. A sentinel lymph node biopsy is often recommended to confirm the cancer has not spread microscopically, distinguishing stage II from stage III disease.
| Substage | Tumor Thickness | Ulceration |
|---|---|---|
| IIA | 1.01–2.0 mm or 2.01–4.0 mm | Absent (thinner) or Absent (thicker) |
| IIB | 2.01–4.0 mm or >4.0 mm | Present or Absent |
| IIC | >4.0 mm | Present |
Stage II Melanoma Treatment Options and Clinical Approaches
The cornerstone of stage II melanoma treatment options is wide local excision (WLE), a surgical procedure that removes the primary tumor along with a defined margin of surrounding healthy tissue. The recommended margin width—typically 1 to 2 centimeters—depends on tumor thickness and location. WLE is generally performed under local anesthesia and is intended to reduce the risk of local recurrence.
Beyond surgery, adjuvant therapy has become an increasingly important component of care, particularly for higher-risk substages (IIB and IIC). Adjuvant immunotherapy with agents such as pembrolizumab or nivolumab has demonstrated improved recurrence-free survival in clinical trials. For tumors harboring a BRAF V600 mutation, targeted therapy combinations may also be considered. Patients are encouraged to discuss eligibility for clinical trials with their oncologist, as research in this area continues to advance rapidly.
- Wide local excision — primary surgical removal with clear margins
- Sentinel lymph node biopsy — staging and risk stratification
- Adjuvant immunotherapy — reduces recurrence risk in higher-risk substages
- Targeted therapy — relevant for BRAF-mutated tumors
Survival Rate, Prognosis, and What to Expect with Stage II Melanoma
The stage 2 melanoma survival rate and prognosis varies meaningfully by substage. According to the American Cancer Society, the five-year relative survival rate is approximately 81–90% for stage IIA, around 70–82% for stage IIB, and approximately 53–65% for stage IIC. These figures reflect population-level data and individual outcomes depend on factors such as age, overall health, tumor biology, and response to treatment.
Understanding stage 2 melanoma what to expect during and after treatment helps patients prepare for the road ahead. Following initial treatment, patients typically undergo structured surveillance with skin exams every three to six months for the first few years, followed by annual evaluations. Imaging studies may be ordered periodically for higher-risk cases. Emotional support, sun protection, and lifestyle adjustments—such as avoiding UV exposure and performing regular self-skin examinations—play an important role in long-term management. Multidisciplinary care involving dermatologists, oncologists, and mental health professionals offers the most comprehensive support.
